No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NARI240621P40000
- 0.35
- 0.000.00%
15min DelayTrading May 23 13:17 ET
0.00High0.00Low
0.00Open0.35Pre Close0 Volume39 Open Interest40.00Strike Price0.00Turnover173.69%IV11.97%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type-0.1321Delta0.0426Gamma128.69Leverage Ratio-0.3140Theta-0.0003Rho-17.00Eff Leverage0.0062Vega
Intraday
- 5D
- Daily
News
Inari Medical(NARI.US) Officer Sells US$237.98K in Common Stock
$Inari Medical(NARI.US)$ Officer Hill, Mitch C. sold 5,000 shares of common stock on Jun 12, 2024 at an average price of $47.6 for a total value of $237.98K.Source: Announcement What is statement of c
(SEC Amendment) Inari Medical(NARI.US) Director Buys US$3 Million in Common Stock
$Inari Medical(NARI.US)$ Director MILDER DONALD B purchased 56,100 shares of common stock on Nov 7, 8, 2023 at an average price of $53.44 for a total value of $3 million.Source: Announcement What is s
Inari Medical: A Strong Buy on Robust 2024 Outlook and Market Expansion Strategies
Director William Hoffman Sells 60,000 Shares of Inari Medical Inc (NARI)
Inari Medical(NARI.US) Director Sells US$3.01 Million in Common Stock
$Inari Medical(NARI.US)$ Director Hoffman William sold 60,000 shares of common stock on May 28, 2024 at an average price of $50.13 for a total value of $3.01 million.Source: Announcement What is state
Inari Medical(NARI.US) Officer Sells US$150K in Common Stock
$Inari Medical(NARI.US)$ Officer Hykes Andrew sold 3,000 shares of common stock on May 28, 2024 at an average price of $50 for a total value of $150K.Source: Announcement What is statement of changes
Comments
CEO Drew Hykes attributes Q4's robust revenue growth to healthy VTE procedure volumes, emerging therapies' traction, and strong international performance. He also highlights progress across all RCTs and the U.S. launch of LimFlow, emphasizing commitment to strong growth and operating profitability.
Press Release: Inari Medical Announces Preliminary 2023 Revenue and 2024 GuidanceThe appointment of Rhonda Robb, with her extensive experience and proven track record, is expected to lead Okami Medical into its next phase of expansion and growth, particularly as the company prepares to commercialize its LOBO Vascular Occlusion System.
The increased insider selling of Inari Medical stock over buying in the last three months along with the year-long trend of insider transactions indicate caution despite high insider ownership. Company risk factors should also be considered alongside insider behavior.
The future looks bleak with predicted negative returns; current investors should consider de-risking. For potential investors, a negative growth outlook raises the risk of holding the Inari Medical stock. Careful examination of further insights and warning signs is advised before investing.
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more